Anxiety Research Today is a free monthly online journal that collates and summarizes the latest research about Anxiety, including details on anxiety disorder, panic attacks, medication, counselling, therapy.

A pyridazine series of alpha2/alpha3 subtype selective GABA A agonists for the treatment of anxiety.

Lewis RT, Blackaby WP, Blackburn T, Jennings AS, Pike A, Wilson RA, Hallett DJ, Cook SM, Ferris P, Marshall GR, Reynolds DS, Sheppard WF, Smith AJ, Sohal B, Stanley J, Tye SJ, Wafford KA, Atack JR

The Neuroscience Research Centre, Merck Sharp & Dohme Research Laboratories, Terlings Park, Eastwick Road, Harlow, Essex CM20 2QR, United Kingdom. richard_t_lewis@btinternet.com

The development of a series of GABA(A) alpha2/alpha3 subtype selective pyridazine based benzodiazepine site agonists as anxiolytic agents with reduced sedative/ataxic potential is described, including the discovery of 16, a remarkably alpha3-selective compound ideal for in vivo study. These ligands are antagonists at the alpha1 subtype, with good CNS penetration and receptor occupancy, and excellent oral bioavailability.

Published 13 April 2006 in J Med Chem, 49(8): 2600-10.
Full-text of this article is available online (may require subscription).

© 2004-2008 Anxiety Research Today. All Rights Reserved.